Abraxas Petroleum Corp
Change company Symbol lookup
Select an option...
AXAS Abraxas Petroleum Corp
CLOEF Cloetta AB
CHH Choice Hotels International Inc
PRAC Productivity Technologies Corp
BAC Bank of America Corp
USAK USA Truck Inc
BABA Alibaba Group Holding Ltd
CTL Centurylink Inc
CSCO Cisco Systems Inc
BGS B&G Foods Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Energy : Oil, Gas & Consumable Fuels | Small Cap Blend
Company profile

Abraxas Petroleum Corporation is an independent energy company. The Company is engaged in the acquisition, exploration, development and production of oil and gas. As of December 31, 2016, the Company's estimated net proved reserves were 44.7 million barrels of oil equivalent (MMBoe), of which 33.6% were classified as proved developed, 74% were oil and natural gas liquids (NGL), and 95% of which (on a PV-10 basis) were operated by the Company. As of December 31, 2016, the Company's daily net production was 6,181 barrels of oil equivalent per day (Boepd), of which 61% was oil or liquids. The Company's oil and gas assets are located in three operating regions: the Rocky Mountain, Permian Basin and onshore Gulf Coast. The Company's properties in the Rocky Mountain region are located in the Williston Basin of North Dakota and Montana, and in the Green River Powder River and Unita Basins of Wyoming and Utah.

Closing Price
Day's Change
-0.0027 (-0.83%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: Aslan Pharmaceuticals' stock soars on heavy volume, after rocketing nearly 9-fold the past week

1:34 pm ET December 2, 2019 (MarketWatch)

Shares of Aslan Pharmaceuticals Ltd. (6497.OT) soared 77% in active premarket trading Monday, after the Singapore-based biopharmaceutical company revealed positive preliminary data from a proof-of-concept study of its atopic dermatitis treatment ASLAN004. The stock was the most active ahead of the open with over 346,000 shares traded. The rally comes after the stock had already rocketed nearly 9-fold from Nov. 21 through Friday, after Aslan published new preclinical data which characterized ASLAN003 as a potential treatment for acute myeloid leukemia. On Monday, the company said in a review of "unclean blinded data," the Eczema Area and Severity Index (EASI) scores of 3 patients who have completed at least one month of low dosing were reduced by 85%, 70% and 59% from baseline. "Whilst the data remains early, we had not anticipated to observe such pronounced improvements in patients enrolled into the lowest dose cohort," said Mark McHale, head of research and development at Aslan. The stock was on track to open Monday at a price that is more than 15 times the Nov. 21 closing price of 44 cents. The stock has more than doubled (up 130%) over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF (IBB) has gained 16% and the S&P 500 has tacked on 7.3%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 02, 2019 13:34 ET (18:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.